Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift - PubMed (original) (raw)
Review
. 2019 Mar;16(2):118-127.
doi: 10.1177/1479164119827611. Epub 2019 Feb 15.
Affiliations
- PMID: 30770030
- DOI: 10.1177/1479164119827611
Free article
Review
Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift
Christopher J Nolan et al. Diab Vasc Dis Res. 2019 Mar.
Free article
Abstract
While few dispute the existence of the metabolic syndrome as a clustering of factors indicative of poor metabolic health, its utility above that of its individual components in the clinical care of individual patients is questioned. This is likely a consequence of the failure of clinicians and scientists to agree on a unifying mechanism to explain the metabolic syndrome. Insulin resistance has most commonly been proposed for this role and is generally considered to be a root causative factor for not only metabolic syndrome but also for its associated conditions of non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), obesity-related type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). An alternative view, for which evidence is mounting, is that hyper-responsiveness of islet β-cells to a hostile environment, such as westernised lifestyle, is primary and that the resulting hyperinsulinaemia drives the other components of the metabolic syndrome. Importantly, within this new conceptual framework, insulin resistance, while always a biomarker and state of poor metabolic health, is not considered to be harmful, but a protective adaptive response of critical tissues including the myocardium against insulin-induced metabolic stress. This major shift in how metabolic syndrome can be considered puts insulin hypersecretion into position as the unifying mechanism. If shown to be correct, this new conceptual framework has major implications for the future prevention and management of the metabolic syndrome, including its associated conditions of NAFLD, PCOS, obesity-related T2D and ASCVD.
Keywords: Cardiovascular diseases; insulin hypersecretion; insulin resistance; insulin-mediated metabolic stress; metabolic syndrome; non-alcoholic fatty liver disease; polycystic ovary syndrome; type 2 diabetes.
Similar articles
- Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
Gastaldelli A. Gastaldelli A. Clin Sci (Lond). 2017 Nov 6;131(22):2701-2704. doi: 10.1042/CS20170987. Print 2017 Nov 15. Clin Sci (Lond). 2017. PMID: 29109303 - Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
Jeanes YM, Reeves S. Jeanes YM, et al. Nutr Res Rev. 2017 Jun;30(1):97-105. doi: 10.1017/S0954422416000287. Epub 2017 Feb 22. Nutr Res Rev. 2017. PMID: 28222828 Review. - Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
Ayonrinde OT, Adams LA, Doherty DA, Mori TA, Beilin LJ, Oddy WH, Hickey M, Sloboda DM, Olynyk JK, Hart R. Ayonrinde OT, et al. J Gastroenterol Hepatol. 2016 May;31(5):980-7. doi: 10.1111/jgh.13241. J Gastroenterol Hepatol. 2016. PMID: 26589977 - Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome.
Wimalawansa SJ. Wimalawansa SJ. J Steroid Biochem Mol Biol. 2018 Jan;175:177-189. doi: 10.1016/j.jsbmb.2016.09.017. Epub 2016 Sep 20. J Steroid Biochem Mol Biol. 2018. PMID: 27662816 Review. - Nonalcoholic fatty liver disease in children and adolescents - Relationship with Polycystic Ovary Syndrome.
Abruzzese GA, Motta AB. Abruzzese GA, et al. Curr Pharm Des. 2015;21(35):5144-50. doi: 10.2174/1381612821666150928105959. Curr Pharm Des. 2015. PMID: 26412465 Review.
Cited by
- Inhibitory Effect of TCF7L2 on Pancreatic β-Cell Dedifferentiation via ERK/MAPK Signaling Pathway in Diabetes.
Wu HH, Ma QW, Liu YM, Wu X, Wen J. Wu HH, et al. Clin Med Insights Endocrinol Diabetes. 2024 Oct 26;17:11795514241295620. doi: 10.1177/11795514241295620. eCollection 2024. Clin Med Insights Endocrinol Diabetes. 2024. PMID: 39473826 Free PMC article. - A Systematic Review of Metabolic Syndrome: Key Correlated Pathologies and Non-Invasive Diagnostic Approaches.
Giangregorio F, Mosconi E, Debellis MG, Provini S, Esposito C, Garolfi M, Oraka S, Kaloudi O, Mustafazade G, Marín-Baselga R, Tung-Chen Y. Giangregorio F, et al. J Clin Med. 2024 Oct 2;13(19):5880. doi: 10.3390/jcm13195880. J Clin Med. 2024. PMID: 39407941 Free PMC article. Review. - Ziziphus jujuba (Jujube) in Metabolic Syndrome: From Traditional Medicine to Scientific Validation.
Ghasemzadeh Rahbardar M, Fazeli Kakhki H, Hosseinzadeh H. Ghasemzadeh Rahbardar M, et al. Curr Nutr Rep. 2024 Dec;13(4):845-866. doi: 10.1007/s13668-024-00581-5. Epub 2024 Oct 1. Curr Nutr Rep. 2024. PMID: 39354208 Review. - Insights into the molecular changes of adipocyte dedifferentiation and its future research opportunities.
Xue M, Liao Y, Jiang W. Xue M, et al. J Lipid Res. 2024 Sep 18;65(11):100644. doi: 10.1016/j.jlr.2024.100644. Online ahead of print. J Lipid Res. 2024. PMID: 39303983 Free PMC article. Review. - Insulin resistance, bone health, and fracture risk.
Armutcu F, McCloskey E. Armutcu F, et al. Osteoporos Int. 2024 Nov;35(11):1909-1917. doi: 10.1007/s00198-024-07227-w. Epub 2024 Sep 12. Osteoporos Int. 2024. PMID: 39264439 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical